NIH-funded research R01 grant

Improving prediction and care for people with chronic kidney disease worldwide

Official title: Chronic Kidney Disease Prognosis Consortium (CKD-PC)

Funded at New York University School of Medicine · NIH-11143943 · Data updated 2026-11-12

This global effort brings together many health studies to improve how doctors predict kidney disease outcomes and guide care for adults with chronic kidney disease.

More Kidney Disease research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionNew York University School of Medicine
NIH-funded
Lab location1 site (New York, United States)
Project startNovember 15, 2023
Project endJune 30, 2028
Funding year2025
Award (this year)$854,984
NIH project number5R01DK100446-13
Project IDNIH-11143943 on NIH RePORTER

Who could benefit from this research

Could help

Adults with chronic kidney disease or reduced kidney function, especially those already followed in clinical cohorts or registries and willing to allow use of their health records or samples, are the most relevant participants.

Less likely to help

People without kidney disease or those looking for an experimental treatment for immediate symptom relief are unlikely to get direct benefit, since this project focuses on prediction, measurement, and guideline development rather than testing new therapies.

What this research studies

You should know that researchers are combining data from hundreds of health studies across many countries to find what best predicts CKD progression and complications. They will run centralized analyses and modern meta-analysis methods to test and refine risk calculators and staging across different regions and patient groups. The team will compare different ways of measuring kidney function (including creatinine and cystatin C) and study links between CKD and heart problems, infections, cancer, frailty, and dementia. The findings are meant to help doctors and guideline groups decide when to test and how to estimate risk for patients like you.

Why it matters

Potential benefit: If successful, this work could give patients clearer risk scores and testing guidance that help catch worsening kidney disease earlier and tailor care more effectively.

How similar studies have gone: Previous phases of the CKD Prognosis Consortium and other large cohort studies have already improved CKD staging and risk tools, though questions remain about global equation changes and broader use of cystatin C.

Where this research is happening

  • New York University School of Medicine
    New York, United States
    Active

Researchers

  • Principal investigator: Coresh, Josef — New York University School of Medicine
  • Study coordinator: Coresh, Josef

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.